FOUNDATION MEDICINE, INC. FMI Income Statement

Foundation medicine, inc. (FMI)

Income statement / TTM

Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Sep'12
Related Party Transaction
Related Party Transaction
Roche [Member]
Product and Service
Product and Service
Molecular Information Services [Member]
Pharma Research and Development Services [Member]
Revenue:
Revenue
-	-	-	-	-	-	-	-	-	77,887	-	74,841	68,141	0	-	0	0	-	-	-	-	-	-
Related-party revenue
-	-	-	-	-	-	-	-	-	0	-	0	0	-	-	0	0	-	-	-	-	-	-
Total revenue
201,417	179,415	152,903	132,814	119,582	112,815	116,865	114,092	110,065	104,286	93,203	85,832	76,881	68,919	61,079	52,061	43,821	35,245	28,990	22,365	0	0	0
Costs and expenses:
Cost of molecular information services
-	-	-	-	-	-	-	-	-	37,807	-	34,956	33,390	31,059	27,434	23,616	18,972	14,572	11,659	9,246	0	0	0
Cost of related-party molecular information services from Roche
-	-	-	-	-	-	-	-	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-
Selling and marketing
67,797	67,771	66,727	65,130	63,228	60,594	57,951	55,328	54,941	53,002	49,030	44,874	38,500	33,128	28,997	25,355	20,500	16,205	12,326	8,573	0	0	0
General and administrative
77,881	75,758	70,340	63,798	59,809	54,664	48,611	43,543	39,730	50,996	50,614	50,786	48,388	30,444	27,302	25,838	25,485	24,415	21,865	16,487	0	0	0
Research and development
93,812	92,083	91,509	86,834	81,673	77,200	67,371	61,959	56,895	48,651	43,883	38,957	34,013	32,402	30,629	29,624	29,382	26,834	24,901	21,634	0	0	0
Total costs and expenses
339,864	330,092	313,846	291,946	277,712	255,833	230,681	211,316	196,476	194,554	182,958	170,875	154,291	127,033	114,362	104,433	94,339	82,026	70,751	55,940	0	0	0
Loss from operations
-138,447	-150,677	-160,943	-159,132	-158,130	-143,018	-113,816	-97,224	-86,411	-90,268	-89,755	-85,043	-77,410	-58,114	-53,283	-52,372	-50,518	-46,781	-41,761	-33,575	0	0	0
Interest (expense) income, net
-3,344	-1,811	-727	-36	384	536	624	0	0	0	-	-	-	-	-	-	-	-	-235	-306	0	0	0
Other income
0	-	204	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-948	-1,461	0	0	0
Interest income
-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	-	-	-	-	-	-
Interest income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-
Interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-
Total other income (expense), net
-	-	-	-	-	-	-	-	-	-	-	1,135	1,118	1,093	1,061	356	-981	-1,126	-1,183	-1,767	0	0	0
Net loss
-141,549	-152,428	-161,466	-158,964	-157,602	-142,338	-113,192	-96,603	-85,917	-89,973	-89,631	-83,908	-76,292	-57,021	-52,222	-52,016	-51,499	-47,907	-42,944	-35,342	0	0	0
Other comprehensive (loss)/income:
Unrealized gain/(loss) on available-for-sale securities
-	-	9	-34	-74	-13	169	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Foreign currency translation adjustment
-280	-155	114	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total other comprehensive (loss)/income
-265	-128	123	44	6	-35	164	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Comprehensive loss
-141,814	-152,556	-161,343	-158,920	-157,596	-142,373	-113,028	-96,569	-85,858	-89,987	-89,809	-83,908	-76,292	-57,021	-52,222	-52,016	-51,499	-47,907	-42,944	-35,342	0	0	0
Net loss
-141,549	-152,428	-161,466	-154,637	0	0	-	0	0	-	-	-	-	-	-	-52,016	-51,499	-47,907	-42,944	-35,342	0	0	0
Accretion of redeemable convertible preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	139	217	0	0	0
Net loss applicable to common stockholders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-43,083	-35,559	0	0	0
Net loss per common share, basic and diluted
-0.90	-1.02	-1.05	-0.90	-1.24	-1.31	-1.01	-0.90	-0.84	-0.50	-0.56	-0.60	-0.98	-0.59	-0.48	-0.46	-0.49	-0.44	4.77	-3.51	-3.34	-2.56	-2.39
Weighted-average common shares outstanding, basic and diluted
37,068	36,792	36,337	36,086	35,660	35,426	35,077	34,949	34,613	34,537	34,535	34,347	33,852	28,609	28,169	28,037	27,876	27,733	27,712	3,565	3,065	2,834	2,331